A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension

Current Eye Research

Volumn 36, Issue 9, 2011, Pages 809-817

  Schachar, Ronald A ^a   Raber, Susan ^a   Courtney, Rachel ^a   Zhang, Min ^a  

^a PFIZER INC   (United States)

Author keywords

E 2 receptor agonist; Intraocular pressure; Ocular hypertension; Open angle glaucoma; Taprenepag isopropyl

Indexed keywords

BIMATOPROST; BRINZOLAMIDE; LATANOPROST; TAPRENEPAG ISOPROPYL ESTER; TIMOLOL;

APPLICATION SITE IRRITATION; ARTICLE; BLURRED VISION; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; CORNEA DISEASE; CORNEA EDEMA; CORNEA EROSION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; EYE IRRITATION; EYE PAIN; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRITIS; LACRIMATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ACUITY;

ACETATES; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 80052001760     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2011.593725     Document Type: Article

References (24)

1. Heijl A, Leske MC, Bengtsson B, et al, Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
2. Costagliola C, dell'Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure-part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009;10:2859-2870.
3. Costagliola C, dell'Omo R, Romano MR, et al. Pharmacotherapy of intraocular pressure: Part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother. 2009;10:2663-2677.
4. Stern FA, Bito LZ. Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1982;22:588-598.
5. Bito LZ, Draga A, Blanco J, Camras CB. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1983;24:312-319.
6. Bito LZ, Srinivasan BD, Baroody RA, Schubert H. Noninvasive observations on eyes of cats after long-term maintenance of reduced intraocular pressure by topical application gf prostaglandin E2. Invest Ophthalmol Vis Sci. 1983;24:376-380.
7. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulation. Pharmacol Ther. 2004;103:147-166.
8. Bito LZ. Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds. Exp Eye Res. 1984;38:181-194.
9. Tsuji F, Hamada M, Shirasawa E. Tachykinins as enhancers of prostaglandin E2-induced intraocular inflammation. Ocul Immunol Inflamm. 1998;6:19-25.
10. Protzman CE, Woodward DF. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype. Invest Ophthalmol Vis Sci. 1990;31:2463-2466.
11. Bhattacherjee P, Mukhopadhyay P, Tilley SL, et al. Bloodaqueous barrier in prostaglandin EP2 receptor knockout mice. Ocul Immunol Inflamm. 2002;10:187-196.
12. Biswas S, Bhattacherjee P, Paterson CA, et al. Ocular inflammatory responses in the EP2 and EP4 receptor knockout mice. Ocul Immunol Inflamm. 2006;14:157-163.
13. Mukhopadhyay P, Geoghegan TE, Patil RV, et al. Detection of EP2, EP4, and FP receptors in human ciliary epithelial and ciliary muscle cells. Biochem Pharmacol. 1997;53:1249-1255.
14. Biswas S, Bhattacherjee P, Paterson CA. Prostaglandin E2 receptor subtypes, EP1, EP2, EP3 and EP4 in human and mouse ocular tissues-a comparative immunohistochemical study. Prostaglandins Leukot Essent Fatty Acids. 2004;71:277-288.
15. Kamphuis W, Schneemann A, van Beek LM, et al. Prostanoid receptor gene expression profile in human trabecular meshwork: A quantitative real-time PCR approach. Invest Ophthalmol Vis Sci. 2001;42:3209-3215.
16. Kamphuis W, Schneemann A, Shichi H, et al. Immunolocalization of prostanoid EP receptor isotypes in human trabecular meshwork. Curr Eye Res. 2004;29:17-26.
17. Schlotzer-Schrehardt U, Zenkel M, Nusing RM. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci. 2002;43:1475-1487.
18. Wang RF, Podos SM, Serle JB, et al. Effect of latanoprost or 8-iso prostaglandin E2 alone and in combination on intraocular pressure in glaucomatous monkey eyes. Arch Ophthalmol. 2000;118:74-77.
19. Kottler UB, Junemann AG, Aigner T, Zenkel, et al. Comparative effects of TGF-beta 1 and TGF-beta 2 on extracellular matrix production, proliferation, migration, and collagen contraction of human Tenon's capsule fibroblasts in pseudoexfoliation and primary open-angle glaucoma. Exp Eye Res. 2005;80:121-134.
20. Fleenor DL, Shepard AR, Helberg PE, et al. TGFbeta2-induced changes in human trabecular meshwork: Implications for intraocular pressure. Invest Ophthalmol Vis Sci. 2006;47:226-234.
21. Robertson JV, Golesic E, Gauldie J, West-Mays JA. Ocular gene transfer of active TGF-beta induces changes in anterior segment morphology and elevated IOP in rats. Invest Ophthalmol Vis Sci. 2010;51:308-318.
22. Choung J, Taylor L, Thomas K, et al. Role of EP2 receptors and cAMP in prostaglandin E2 regulated expression of type I collagen a1, lysyl oxidase, and cyclooxygenase-1 genes in human embryo lung fibroblasts. J Cell Biochem. 1998;71:254-263.
23. Tian M, Schiemann WP. PGE2 receptor EP2 mediates the antagonistic effect of COX-2 on TGF-β signaling during mammary tumorigenesis. FASEB J. 2010;24:1105-1116.
24. Serle JB, Wang R-F, Mittag TW, et al. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes. J Glaucoma. 2001;10:215-219.